Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and sandimmun neoral
Introduction
Nowadays, numerous efforts are being made to enhance the oral bioavailability of polypeptides in order to increase their clinical efficacy. The incorporation of the active component into lipid vesicles is very attractive. Advantages include increased solubility and protection of the polypeptides from the aggressive conditions present in the gastrointestinal tract (Arien et al., 1994, Arien et al., 1995). Furthermore, the biomembrane similarity of the lecithin material and the small particle size of the vesicles may result in rapid absorption (Aungust, 1993). It has been reported that oral administration of liposomes loaded with calcitonin led to hypocalcemic effect in the rat 1 h after the application (Fukunaga et al., 1991).
Cyclosporin A (CsA) is a lipophilic cyclic polypeptide containing 11 amino acids and was reported as a typical drug with the worst and non-regular absorption (Klompmaker et al., 1993). The present study was undertaken to characterize the incorporation of CsA into lecithin vesicular system and to compare its pharmacokinetics behavior in rabbits with Sandiummun Neoral® (CsA-NEO). Sandiummun Neoral® is a highly recommended new microemulsion formulation concentrated CsA (Kovarik et al., 1994).
Section snippets
Materials
Soybean lipid (purity >80%, lot number: 980607) was purchased from Shanghai Fuda pharmaceutical manufacturing factory (China) and lecithin was freshly prepared by column chromatography on aluminum oxide according to the reported method (Singelton et al., 1964). Only lecithin with purity >95% was used in this study. CsA powder (USP 23, lot number: 040396) was obtained from Galena (Czech Republic). Methanol, chloroform, sodium chloride and other reagents, all p.a. were products of Nanjing
Physical properties of vesicles
CsA-VES suspension was transparent colloidal dispersions with average diameter of 77.6 nm and the polydispersity index of 45.6%. Zeta potential was −13 mV.
Fig. 1 showed the transmission electron photomicrographs of vesicles. It was evident that the particles were approximately spherical with obvious whorls.
Determination of CsA
The regression equation for CsA content (μg/ml) in ethanol solution ranging from 0.1 to 4 μg/ml was A=7.52×103C−74.66 (r2=0.9999). The mean recovery was 97.4±5.9% (n=3). Precision assay
Discussion
CsA is a potent immunosuppressive drug and has been utilized clinically in the prevention of organ rejection (Mcevoy, 1995). Due to its high lipophilicity, poor solubility in aqueous fluids, the existence of an absorption window in the small intestine (Reymond et al., 1988) and relatively high molecular weight, the mean absolute bioavailability of CsA is approximately only 30%, when the drug is administered as Sandiummun®, a crude oil-in-water emulsion (Mcevoy, 1995). In order to increase
Acknowledgements
This research work is granted by the National Natural Science Foundation of China, with project number 39930200.
References (13)
- et al.
Calcitonin-loaded liposomes: stability under acidic conditions and bile salts-induced disruption resulting in calcitonin–phospholipid complex formation
Biochim. Biophys. Acta
(1994) - et al.
Reduced inter- and intra-individual variability in cyclosporine pharmacokinetics from a microemulsion formulation
J. Pharm. Sci.
(1994) - et al.
Pharmacokinetic and pharmacodynamic evaluation of liposomal cyclosporine
Int. J. Pharm.
(1989) - et al.
Cholate-induced disruption of calcitonin-loaded liposomes: formation of trypsin-resistant lipid-calcitonin-cholate complexes
Pharm. Res.
(1995) Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation
J. Pharm. Sci.
(1993)- et al.
Liposome-entrapped calcitonin and parathyroid hormone are orally effective in rats
Horm. Metab. Res.
(1991)
Cited by (48)
Dual Formulation and Interaction Strategies to Enhance the Oral Bioavailability of Paclitaxel
2020, Journal of Pharmaceutical SciencesCitation Excerpt :Oral administration of PTX-SMEDDS formulation and CSA was carried out through a pediatric feeding tube. The time of the CSA pretreatment was selected to make sure that CSA plasma concentration is at its maximum value.23,24 Group 5, received 5 mg/kg IV PTX, as 1.5 mL of hydro-alcoholic solution, through a marginal ear vein catheter (Argyle™ polyurethane umbilical vessel catheter, 0.8 mm × 25 cm, Covidien Inc.
A novel approach to the oral delivery of bionanostructures for systemic disease
2017, Nanostructures for Oral MedicinePreparation and evaluation of liposome-encapsulated codrug LMX
2012, International Journal of PharmaceuticsCitation Excerpt :Most importantly, the similarity between liposomal lipid bilayers and biomembranes and the suitable size of liposomes significantly facilitate oral absorption (Aungust, 1993). More recently, for poorly water-soluble drugs, substantial enhancement in bioavailability or in vivo efficacy has been observed following liposomal encapsulation (Guo et al., 2001; Xiao et al., 2006). The objective of the present study was to synthesize LMX, and develop a liposomal formulation of it for oral and intravenous administration.
The use of ciclosporin A in veterinary dermatology
2012, Veterinary JournalCitation Excerpt :When employed at the high dosage of 15 mg/kg daily, CsA may be of benefit in the management of pemphigus foliaceus and erythematosus (Rosenkrantz, 2004), but there is no convincing evidence that it is of benefit in the treatment of feline epitheliotropic lymphoma (Rosenkrantz et al., 1989). CsA is currently not licensed for use in rabbits but Guo et al. (2001) suggested that the drug can be used in rabbits and rodents, and it has been employed successfully to treat sebaceous adenitis when combined with oral administration of multiple medium-chain triglycerides (Jassies-van der Lee et al., 2009). In dogs, CsA should be used with caution in animals with suspected viral, fungal or protozoal (leishmaniosis) infections (Navarro et al., 2008; Ramsey, 2008).
Applications of X-ray scattering in pharmaceutical science
2011, International Journal of PharmaceuticsCitation Excerpt :Liposomes were first proposed as drug delivery vehicles by Gregoriadis (1973). Since then, liposomes have been extensively used for various delivery applications, including commercially available pharmaceutical products since the early 90 s (Davidson et al., 1991; Guaglianone et al., 1994), and since have been developed for the encapsulation of chemotherapeutic agents (Niu et al., 2010; Pili et al., 2010; Van Bommel and Crommelin, 1984), anti-infectives: amphotericin B (van Etten et al., 1995), vaccines (Gregoriadis et al., 1999), hormones (Shahiwala and Misra, 2004), immuno-modulators (Guo et al., 2001), analgesics (Hung et al., 1995), etc. (Zhang et al., 2007). Liposomes have also been proposed as an encapsulating agent for carboranes, in boron neutron capture therapy (Ristori et al., 2005; Salvati et al., 2007; Soloway et al., 1998).
Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt
2009, International Journal of Pharmaceutics